↑Harrison, Baum, Gunn et Younes, « Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease », The American Journal of Gastroenterology, vol. 116, no 12, , p. 2399–2409 (ISSN0002-9270, PMID34382947, PMCID8631161, DOI10.14309/ajg.0000000000001375)
↑Finnigan, Cassar, Koziel et Pradines, « Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study », eClinicalMedicine, vol. 59, , p. 101946 (PMID37223439, PMCID10102537, DOI10.1016/j.eclinm.2023.101946)
↑Park, Brian. "Orally Active Amino Acid Mixture Fast Tracked for NASH With Liver Fibrosis." Medical Bag, 16 Feb. 2022, p. NA. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A693790920/HRCA?u=anon~8aede0d3&sid=googleScholar&xid=1e146086. Accessed 3 Dec. 2023.
↑Daou, Viader, Cokol et Nitzel, « A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models », Scientific Reports, vol. 11, no 1, , p. 11861 (PMID34088912, PMCID8178416, DOI10.1038/s41598-021-88913-1, Bibcode2021NatSR..1111861D)